Oral Dexmedetomidine in Pediatric MRI

Starting soon · Phase 1

Conditions studied: Anesthesia

In brief

The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI.

Key facts

Study ID

NCT05619627

Run by

Soroush Merchant

People needed

18

Starts

2026-11-01

Expected to finish

2028-03-01

Last updated by the study team

2026-08-04

Who can join

Age: 3 and older, up to 6. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participants 3-6 years old, male and female, all races and ethnicities
• Requiring a clinically indicated MRI with general anesthesia

You may not qualify if…

• Refusal to take oral dexmedetomidine
• Known allergy to dexmedetomidine
• Inability to take dexmedetomidine at least 90 minutes prior to start of the MRI
• Medical contraindications to administration of dexmedetomidine including:
• Unstable cardiac status including life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction
• Current use of digoxin
• Moya Moya disease
• New onset stroke
• American Society of Anesthesiologists (ASA) physical status classification > II
• Contraindications to administering sedation including:
• Active and uncontrolled gastroesophageal reflux
• Active and uncontrolled vomiting
• Current or recent history of apnea
• Active respiratory disease including pneumonia, bronchitis, respiratory syncytial virus infection, asthma exacerbation
• Craniofacial anomalies
• Inability to have MRI scans
• Non-English speaking volunteers

Where it is running

• Children's Mercy Hospital — Kansas City, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.